Epigral Ltd (NSE: EPIGRAL, BSE: 543332) is an Ahmedabad, Gujarat-based company in the Plastic and Synthetic Resins industry. With a market capitalisation of ₹4,059 Cr, it ranks #932 by market cap among the 6,197 Indian listed companies on FinBizNet, and #7 of 63 in Plastic and Synthetic Resins. At ₹954.40 (as of 16 Nov 2026), the share price is 37.8% below its 52-week high of ₹1,535.20 and 18.3% above its 52-week low of ₹807.00. The share price is down 42.3% over one year and down 14.9% over three months.
| Current Price | ₹954.40 |
|---|---|
| Market Cap | ₹4,059 Cr |
| NSE Symbol | EPIGRAL |
| BSE Code | 543332 |
| Sector | Materials > Chemicals > Commodity Chemicals |
| Sub-Industry | Commodity Chemicals > Plastic and Synthetic Resins |
| P/E Ratio | 12.2 |
| Return on Equity | 16.09% |
| Return on Assets | 7.51% |
| 52-Week Range | ₹807.00 – ₹1,535.20 |
| 1-Year Price Change | -42.3% |
| 3-Month Price Change | -14.9% |
| Beta (1Y) | 0.66 |
| Dividend Yield | 0.53% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.epigral.com |
| Revenue | ₹746 Cr |
|---|---|
| Net Profit | ₹65 Cr |
| Net Margin | 8.7% |
| EPS (Basic) | ₹15.09 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Epigral Ltd reported revenue of ₹746 Cr in Q2 FY27, up 27.0% from ₹587 Cr in Q2 FY26 and up 5.8% from ₹705 Cr in Q1 FY27. It posted a net profit of ₹65 Cr for the quarter, against a net profit of ₹51 Cr in Q2 FY26 (up 27.1%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹587 Cr (Q2 FY26) to ₹746 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹746 Cr | ₹65 Cr | 8.7% |
| Q1 FY27 | ₹705 Cr | ₹100 Cr | 14.1% |
| Q4 FY26 | ₹736 Cr | ₹81 Cr | 11.0% |
| Q3 FY26 | ₹597 Cr | ₹39 Cr | 6.5% |
| Q2 FY26 | ₹587 Cr | ₹51 Cr | 8.7% |
| Q1 FY26 | ₹607 Cr | ₹161 Cr | 26.5% |
| Q4 FY25 | ₹628 Cr | ₹87 Cr | 13.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 68.83% of Epigral Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 47.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins and compounds, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar hybrid power plant. Its products are used in CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.
1. Chloro Alkali & Its Derivatives-This segment engages in manufacturing of chloro alkali and its derivatives. 2. NA-NA 3. NA-NA 4. NA-NA
1. Chloro Alkali & Its Derivatives-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Garware Hi-Tech Films Ltd | ₹17,955 Cr | 52.8 | 13.45% | ₹696 Cr | +121.0% |
| Supreme Petrochem Ltd | ₹13,198 Cr | 40.2 | 14.32% | ₹1,984 Cr | +6.9% |
| Finolex Industries Ltd. | ₹9,262 Cr | 15.5 | 9.73% | ₹1,094 Cr | -18.4% |
| Kingfa Science & Technology Ltd | ₹8,660 Cr | 44.4 | 17.41% | ₹723 Cr | +42.1% |
| Swan Corp Ltd | ₹7,492 Cr | 27.3 | 3.00% | ₹1,046 Cr | -50.4% |
| Kama Holdings Ltd | ₹6,970 Cr | 7.5 | 12.93% | — | — |
| Epigral Ltd | ₹4,059 Cr | 12.2 | 16.09% | ₹746 Cr | -42.3% |
| Responsive Industries Ltd. | ₹3,630 Cr | 24.4 | 10.22% | ₹205 Cr | -32.6% |
| Ineos Styrolution India Ltd | ₹3,356 Cr | 18.4 | 14.43% | ₹994 Cr | -19.9% |
Listed by market capitalisation. Ratios are shown for context only.
Epigral Ltd is trading at ₹954.40, with a market capitalisation of ₹4,059 Cr.
Epigral Ltd operates in the Materials > Chemicals > Commodity Chemicals space (Commodity Chemicals > Plastic and Synthetic Resins).
Epigral Ltd has a P/E of 12.2 and a return on equity of 16.09%.
Epigral Ltd is listed on the NSE under the symbol EPIGRAL and on the BSE under the scrip code 543332.
Epigral Ltd's share price is down 42.3% over one year and down 14.9% over three months. Its 52-week range is ₹807.00 to ₹1,535.20.
In Q2 FY27, Epigral Ltd reported revenue of ₹746 Cr and net profit of ₹65 Cr, with basic EPS of ₹15.09 (consolidated, parsed from the company's exchange filing).
Epigral Ltd reported revenue of ₹746 Cr in Q2 FY27, up 27.0% from ₹587 Cr in Q2 FY26 and up 5.8% from ₹705 Cr in Q1 FY27.
Promoters held 68.83% of Epigral Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.